[Gastroenterology] To understand how hepatocytes cope with mitotic challenges, the authors established a high-quality in vivo CRISPRi screen in regenerating mouse liver. By cross-referencing with gene essentiality data in cell lines, they identified genes required specifically by hepatocytes for proliferation.

[Proceedings of the National Academy of Sciences of the United States of America] Scientists developed an activated hepatic stellate cells (aHSCs)-targeted nanoplex that activates the stimulator of interferon genes pathway to induce senescence in aHSCs, while promoting endogenous immune surveillance-mediated clearance of aHSCs.

[Cell Reports] Researchers developed a patient-derived liver cancer organoid platform for high-throughput drug screening, identifying promising drug candidates and combination therapies across heterogeneous tumors.

[Cancer Letters] Investigators reported a previously unknown mechanism of acyl CoA synthetase 4 (ACSL4) regulation involving acetylation at the lysine 49 (K49) site by the acetyltransferase MOF.

[Oncogene] Using lineage-specific liver-targeted PTEN-deficient mouse models, we demonstrate that PTEN loss drives cellular dedifferentiation and tumorigenesis, a process that is critically dependent on AKT2.

[Journal of Gastroenterology and Hepatology] Researchers investigated the interaction between ferroptosis and lenvatinib resistance in HCC and explores the underlying mechanisms.

[European Journal of Pharmacology] Investigators highlight how dynamic chromatin accessibility regulates hepatic stellate cell activation and extracellular matrix deposition, revealing epigenetic targets for treating liver fibrosis.

[Keck School of Medicine of USC] Researchers at the Keck School of Medicine of USC and USC Norris Comprehensive Cancer Center have received two grants from the National Institutes of Health (NIH) totaling $7.5 million to study whether exposure to per- and polyfluoroalkyl substances (PFAS) increases the risk of liver cancer and endometrial cancer.

[Gilead Sciences, Inc. (BioSpace)] Gilead Sciences, Inc. announced that the European Commission has granted marketing authorization for Trodelvy® in combination with Keytruday® for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who have not received prior systemic therapy for metastatic disease.

[Science Advances] Researchers engineered a tunable hyaluronan-elastin-like protein hydrogel to independently control ligand presentation and matrix viscoelasticity. Using dynamic covalent chemistry, they developed hydrogels with matched stiffness but distinct stress relaxation profiles.

[Signal Transduction and Targeted Therapy] The authors synthesize how cancer-associated adipocytes and adipose dynamics drive oncogenesis, progression and therapeutic failure and highlight actionable nodes within the adipose–tumor axis for precision oncology.

[Proceedings of the National Academy of Sciences of the United States of America] Researchers developed an activation of hepatic stellate cell-targeted nanocomplex to remodel a rigid fibrotic barrier. This platform inhibits the fibrotic process by inducing cellular senescence and activating endogenous immune surveillance.